Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2002 1
2003 5
2004 2
2005 5
2006 1
2007 2
2008 5
2009 12
2010 10
2011 4
2012 12
2013 12
2014 9
2015 7
2016 7
2017 5
2018 3
2019 10
2020 5
2021 8
2022 4
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
Adalimumab in Patients with Active Noninfectious Uveitis.
Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D, Chu DS, Camez A, Kwatra NV, Song AP, Kron M, Tari S, Suhler EB. Jaffe GJ, et al. Among authors: suhler eb. N Engl J Med. 2016 Sep 8;375(10):932-43. doi: 10.1056/NEJMoa1509852. N Engl J Med. 2016. PMID: 27602665 Free article. Clinical Trial.
Rituximab for Ocular Inflammatory Disease.
Cunningham ET Jr, Ng C, Suhler EB, Smit DP. Cunningham ET Jr, et al. Among authors: suhler eb. Ocul Immunol Inflamm. 2022 Aug;30(6):1300-1302. doi: 10.1080/09273948.2022.2141034. Ocul Immunol Inflamm. 2022. PMID: 36379016 No abstract available.
Drug-induced uveitis.
Shifera AS, Kopplin L, Lin P, Suhler EB. Shifera AS, et al. Among authors: suhler eb. Int Ophthalmol Clin. 2015 Spring;55(2):47-65. doi: 10.1097/IIO.0000000000000059. Int Ophthalmol Clin. 2015. PMID: 25730619 Review. No abstract available.
Drug-induced inflammation in patients on TNFα inhibitors.
Cunningham ET Jr, Pasadhika S, Suhler EB, Zierhut M. Cunningham ET Jr, et al. Among authors: suhler eb. Ocul Immunol Inflamm. 2012 Feb;20(1):2-5. doi: 10.3109/09273948.2011.644383. Ocul Immunol Inflamm. 2012. PMID: 22324894 No abstract available.
Incidence of and Risk Factors for Cataract in Anterior Uveitis.
Papaliodis GN, Rosner BA, Dreger KA, Fitzgerald TD, Artornsombudh P, Kothari S, Gangaputra SS, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Sen HN, Suhler EB, Thorne JE, Bhatt NP, Foster CS, Jabs DA, Pak CM, Ying GS, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study Research Group. Papaliodis GN, et al. Among authors: suhler eb. Am J Ophthalmol. 2023 Oct;254:221-232. doi: 10.1016/j.ajo.2023.06.021. Epub 2023 Jul 5. Am J Ophthalmol. 2023. PMID: 37414328
The future of uveitis treatment.
Lin P, Suhler EB, Rosenbaum JT. Lin P, et al. Among authors: suhler eb. Ophthalmology. 2014 Jan;121(1):365-376. doi: 10.1016/j.ophtha.2013.08.029. Epub 2013 Oct 26. Ophthalmology. 2014. PMID: 24169255 Free PMC article. Review.
Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality.
Kempen JH, Newcomb CW, Washington TL, Foster CS, Sobrin L, Thorne JE, Jabs DA, Suhler EB, Rosenbaum JT, Sen HN, Levy-Clarke GA, Nussenblatt RB, Bhatt NP, Lowder CY, Goldstein DA, Leiderman YI, Acharya NR, Holland GN, Read RW, Dunn JP, Dreger KA, Artornsombudh P, Begum HA, Fitzgerald TD, Kothari S, Payal AR, Daniel E, Gangaputra SS, Kaçmaz RO, Liesegang TL, Pujari SS, Khachatryan N, Maghsoudlou A, Suga HK, Pak CM, Helzlsouer KJ, Buchanich JM; Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Research Group. Kempen JH, et al. Among authors: suhler eb. Ophthalmology. 2023 Dec;130(12):1258-1268. doi: 10.1016/j.ophtha.2023.07.023. Epub 2023 Jul 26. Ophthalmology. 2023. PMID: 37499954
Adalimumab for Ocular Inflammation.
Durrani K, Kempen JH, Ying GS, Kacmaz RO, Artornsombudh P, Rosenbaum JT, Suhler EB, Thorne JE, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Foster CS Md Facs, Systemic Immunosuppressive Therapy For Eye Diseases Site Research Group. Durrani K, et al. Among authors: suhler eb. Ocul Immunol Inflamm. 2017 Jun;25(3):405-412. doi: 10.3109/09273948.2015.1134581. Epub 2016 Mar 22. Ocul Immunol Inflamm. 2017. PMID: 27003323 Free PMC article.
Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
Suhler EB, Jaffe GJ, Fortin E, Lim LL, Merrill PT, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Van Calster J, Cimino L, Adan A, Goto H, Kaburaki T, Kramer M, Vitale AT, Kron M, Song AP, Liu J, Pathai S, Douglas KM, Schlaen A, Muccioli C, Van Velthoven MEJ, Zierhut M, Rosenbaum JT. Suhler EB, et al. Ophthalmology. 2021 Jun;128(6):899-909. doi: 10.1016/j.ophtha.2020.10.036. Epub 2020 Nov 3. Ophthalmology. 2021. PMID: 33157077 Free article. Clinical Trial.
119 results